CBIO Stock Overview
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Catalyst Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.67 |
| 52 Week High | US$11.10 |
| 52 Week Low | US$2.83 |
| Beta | 1.29 |
| 1 Month Change | 6.01% |
| 3 Month Change | 46.09% |
| 1 Year Change | -8.39% |
| 3 Year Change | -90.64% |
| 5 Year Change | -95.39% |
| Change since IPO | -99.62% |
Recent News & Updates
Recent updates
Catalyst Biosciences declares special one-time dividend of $1.43
Aug 25Catalyst Biosciences: Shareholders Should Reap Benefits From Owning The Stock
Aug 15Catalyst Biosciences plans to distribute $65M cash to stockholders
Jun 29Companies Like Catalyst Biosciences (NASDAQ:CBIO) Could Be Quite Risky
Jan 11
Circling Back On Catalyst Biosciences
Dec 08Shareholders May Not Be So Generous With Catalyst Biosciences, Inc.'s (NASDAQ:CBIO) CEO Compensation And Here's Why
Jun 03Catalyst Biosciences (NASDAQ:CBIO) Will Have To Spend Its Cash Wisely
May 18Catalyst Biosciences EPS misses by $0.12, beats on revenue
May 06Would Shareholders Who Purchased Catalyst Biosciences' (NASDAQ:CBIO) Stock Five Years Be Happy With The Share price Today?
Mar 09We're Hopeful That Catalyst Biosciences (NASDAQ:CBIO) Will Use Its Cash Wisely
Feb 01Catalyst Biosciences announces closing of $50M capital raise
Jan 29Do Institutions Own Catalyst Biosciences, Inc. (NASDAQ:CBIO) Shares?
Dec 28Catalyst Biosciences' MarzAA fast track'd for episodic bleeding in hemophilia patients
Dec 02What We Learned About Catalyst Biosciences' (NASDAQ:CBIO) CEO Pay
Dec 02Catalyst Biosciences (CBIO) Presents At Stifel 2020 Virtual Healthcare Conference - Slideshow
Nov 18Catalyst Biosciences: After 2 Fundraisings, A Lengthy Wait For Pivotal Trial Data Is Next
Nov 14Shareholder Returns
| CBIO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 18.6% | 1.3% | 3.3% |
| 1Y | -8.4% | 3.0% | 25.0% |
Return vs Industry: CBIO underperformed the US Biotechs industry which returned -4.2% over the past year.
Return vs Market: CBIO underperformed the US Market which returned 14.1% over the past year.
Price Volatility
| CBIO volatility | |
|---|---|
| CBIO Average Weekly Movement | 20.1% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CBIO's share price has been volatile over the past 3 months.
Volatility Over Time: CBIO's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 7 | Nassim Usman | www.catalystbiosciences.com |
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.
Catalyst Biosciences, Inc. Fundamentals Summary
| CBIO fundamental statistics | |
|---|---|
| Market cap | US$19.42m |
| Earnings (TTM) | -US$44.24m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs CBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CBIO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$1.97m |
| Gross Profit | -US$1.97m |
| Other Expenses | US$42.27m |
| Earnings | -US$44.24m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -17.47 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CBIO perform over the long term?
See historical performance and comparison